Genomic characterization of therapy-associated polyposis reveals an alkylating mutational signature from prior treatment

This study characterizes therapy-associated polyposis (TAP) as a distinct syndrome in childhood cancer survivors marked by long latency, heterogeneous histology, and a specific alkylating-agent mutational signature (SBS25) that drives extensive genomic instability and secondary malignancies, thereby distinguishing it from hereditary forms and supporting tailored surveillance strategies.

The Gist

Imagine your body as a vast, bustling city. The cells are the citizens, and the DNA is the city's master blueprint, telling every citizen exactly what to do and when to retire.

This paper tells the story of a specific group of people who survived childhood cancer, only to face a new, unexpected problem decades later: their "colony" of cells in the gut started growing out of control, forming too many growths (polyps). The researchers wanted to figure out why this was happening and how it was different from other known causes.

Here is the story of their discovery, broken down into simple concepts:

1. The "Time Bomb" Effect

Think of the cancer treatments these patients received as children (like strong chemotherapy or radiation) as a powerful storm that swept through the city. The storm saved the city from a bigger disaster (the original cancer), but it left behind some hidden damage.

Decades later, this damage didn't just sit there; it started to cause trouble. The researchers found that these patients developed a condition called Therapy-Associated Polyposis (TAP).

• The Delay: It took an average of 29 years for the trouble to start. It's like a time bomb that was set off when they were kids, but it didn't explode until they were in their late 40s.
• The Culprit: The study found that the "storm" was often caused by a specific type of chemical weapon used in chemotherapy called alkylating agents. These are like "glue" that accidentally sticks to the DNA, causing it to get messy and break.

2. Ruling Out the "Family Curse"

When doctors see a lot of growths in the gut, they often suspect a "family curse" (a genetic disease passed down from parents). One famous genetic glitch is called HMPS, which is like a broken instruction manual that tells the body to build too many walls.

The researchers checked the DNA of these patients to see if they had this "family curse."

• The Verdict: They looked for the specific "broken page" (a duplication in a gene called GREM1) and didn't find it.
• The Conclusion: This wasn't a family inheritance. It was an acquired injury. The damage happened because of the treatment they received, not because of their parents.

3. The "Scars" on the Blueprint

To understand what happened, the scientists looked at the DNA of the growths like detectives examining a crime scene. They were looking for "fingerprints" (mutational signatures) left behind by the original treatment.

• The Smoking Gun: They found a very specific fingerprint called SBS25. This fingerprint is unique to the "glue" chemicals (alkylating agents) used in the past. It's like finding a specific brand of shoe print at a crime scene that only the original attacker wore.
• The Damage: The DNA in these patients wasn't just slightly messy; it was fragmented. Imagine a library where the books aren't just missing pages, but the entire shelves have been smashed and the books are in pieces. The patients' cells had far more broken DNA than people with standard genetic diseases.

4. The "Confused Workers" (Organoids)

To see how this damage affected the cells' behavior, the researchers grew tiny, miniature versions of the gut in a lab dish (called organoids).

• The Observation: When they grew cells from these patients, the "workers" (stem cells) couldn't figure out what job to do. They were stuck in a state of confusion, unable to mature into healthy, specialized cells.
• The Metaphor: It's like a construction crew that has been hit by a chemical spill; they keep building, but they can't finish the buildings or know what the final structure should look like. This confusion leads to the formation of polyps.

The Big Takeaway

This paper is a wake-up call for the medical world. It tells us that for survivors of childhood cancer, the gut is a "sensitive zone" that remembers the trauma of treatment decades later.

• It's not a genetic disease: You can't blame the parents; it's a side effect of the life-saving treatment.
• It's distinct: It looks different from other types of colon polyps because it carries the specific "scars" of chemotherapy.
• The Solution: Because we now know this happens, doctors need to start checking these survivors' guts much earlier and more often than the general population. It's like putting up extra traffic lights in a neighborhood that we now know has a history of potholes, to prevent accidents before they happen.

In short: The treatment saved their lives, but it left a hidden, slow-burning injury in their DNA that needs special monitoring.

Technical Summary

1. Problem Statement

Therapy-Associated Polyposis (TAP) is a rare but increasingly significant condition affecting survivors of childhood and young adult cancers (CYAC). Unlike hereditary polyposis syndromes (e.g., Familial Adenomatous Polyposis or FAP), TAP develops decades after initial cancer treatment, typically following exposure to abdominopelvic radiation and/or alkylating chemotherapy agents.

• Clinical Context: As CYAC survival rates improve, the burden of late gastrointestinal (GI) toxicity is rising. Survivors face an ~11-fold increased risk of colorectal cancer (CRC) compared to the general population.
• Knowledge Gap: The molecular etiology of TAP remains poorly understood. It is unclear whether TAP is driven by germline mutations, somatic therapy-induced damage, or a combination of both. Furthermore, the specific mutational signatures and genomic architecture distinguishing TAP from hereditary syndromes have not been systematically characterized.

2. Methodology

The authors conducted the largest clinicopathological and genomic study of TAP to date, analyzing a cohort of 29 patients.

• Cohort Characteristics: Patients had a median age of 49 at TAP diagnosis, with a median latency of 29 years post-primary cancer treatment. The primary malignancies were predominantly Hodgkin lymphoma (65.5%).
• Clinical Data Collection: Detailed review of treatment history (chemotherapy agents, radiation fields), family history, and secondary cancer incidence.
• Genomic Analysis:
  • Whole-Genome Sequencing (WGS): Performed on adenomas from TAP patients ($n=8$), FAP controls ($n=2$), and Hereditary Mixed Polyposis Syndrome (HMPS) controls ($n=4$).
  • Structural Variant (SV) Analysis: Used tools like CNVnator and manual review in IGV to detect large deletions, insertions, and copy number variations (CNVs). Specifically tested for the canonical 40-kb GREM1 duplication associated with HMPS.
  • Mutational Signature Profiling: Analyzed single-base substitution (SBS) signatures to identify the mutational processes driving tumorigenesis (e.g., SBS1, SBS5, SBS25, SBS31).
  • Functional Validation: Generated patient-derived organoids (PDOs) from paired normal and adenoma tissue of a TAP patient to assess differentiation capacity.
  • Immunohistochemistry (IHC): Assessed GREM1 protein expression levels.

3. Key Contributions

• First Comprehensive Genomic Profile of TAP: This study provides the first deep molecular characterization of TAP, moving beyond clinical observation to define its genomic landscape.
• Exclusion of HMPS: The study definitively ruled out Hereditary Mixed Polyposis Syndrome as the primary driver in this cohort by demonstrating the absence of the GREM1 germline duplication and lack of consistent GREM1 overexpression.
• Identification of Therapy-Specific Signatures: The research successfully linked the mutational burden in TAP adenomas directly to prior alkylating chemotherapy, identifying a specific "molecular scar."
• Functional Modeling: Establishment of TAP-derived organoid models to study therapy-induced stem cell dysfunction.

4. Key Results

A. Clinical and Histopathological Features

• Latency and Demographics: TAP presents with a long latency (median 29 years) and at a younger age (median 49) than sporadic polyposis.
• Treatment History: 78% of patients received alkylating agents (mechlorethamine, procarbazine, dacarbazine, cyclophosphamide).
• Secondary Malignancies: High rates of secondary cancers were observed, including basal cell carcinoma (27.5%), breast cancer (50% of females), and colorectal/lung cancers.
• Histology: Polyps were predominantly adenomatous but showed mixed subtypes.
• Family History: 31% of patients had a family history of colonic polyps, initially raising suspicion for a hereditary syndrome, which was subsequently disproven by genomic testing.

B. Genomic Architecture

• HMPS Exclusion: No GREM1 40-kb duplications were found in TAP samples, unlike the positive controls (HMPS). GREM1 expression was heterogeneous and not consistently overexpressed.
• Structural Variants: TAP adenomas exhibited significantly more extensive genome fragmentation and a higher burden of large deletions and insertions (>1 kb) compared to FAP adenomas. This suggests profound structural genomic injury distinct from the APC-driven pathway of FAP.

C. Mutational Signatures

• Age-Related Signatures: All samples showed contributions from SBS1 and SBS5 (age-associated), accounting for 45–70% of mutations.
• Alkylating Agent Signature (SBS25): A robust and pervasive SBS25 signature was detected in TAP adenomas.
  • SBS25 is characterized by T>A transversions.
  • It is mechanistically linked to methyl-hydrazine-based alkylating agents (procarbazine, dacarbazine).
  • Crucially, this signature was present even in samples lacking matched normal tissue, confirming it as a somatic scar of prior therapy.
• Platinum Signature (SBS31): Minimal contribution, indicating platinum agents were not the primary driver of the observed mutational landscape in this cohort.

D. Functional Consequences

• Organoid Differentiation: TAP-derived adenoma organoids showed impaired differentiation compared to matched normal organoids. This phenotype mirrors defects seen in FAP organoids, suggesting persistent therapy-induced stem cell dysfunction and altered epithelial homeostasis.

5. Significance and Implications

• Redefining TAP: The study establishes TAP as a distinct polyposis syndrome characterized by heterogeneous histology, long latency, profound structural genomic injury, and chemotherapy-specific mutational scars, rather than a germline disorder.
• Mechanistic Insight: The findings provide a molecular mechanism linking alkylating chemotherapy to late-onset GI polyposis via the accumulation of specific mutational signatures (SBS25) and structural damage.
• Clinical Recommendations:
  • Surveillance: Given the high risk and early onset of polyposis in CYAC survivors, early and tailored GI surveillance is critical.
  • Risk Stratification: Patients treated with alkylating agents require specific monitoring for secondary malignancies and polyposis, distinct from standard screening protocols.
• Future Directions: The patient-derived organoid models offer a tractable platform for future mechanistic studies and drug testing to mitigate therapy-induced GI toxicity.

Limitations: The study acknowledges a small sample size ($n=29$), the lack of matched normal tissue for many cases (relying on public databases for filtering), and variability in sequencing depth which may impact CNV calling accuracy.